Explore the latest advancements in ADNI genetics research, including updates on sample collections, longitudinal DNA and RNA studies, pathway analysis, genetic signal to therapeutics, use of genetic data, and publications on ADNI endophenotypes. The content also covers the most frequently reported g

0 views • 18 slides

Autosomal Dominant Alzheimer Disease (ADAD) and Sporadic Late Onset Alzheimer Disease (LOAD) show distinct clinical presentations, neuropathological features, and rates of progression. The DIAN-ADNI Comparison Study aims to investigate if ADAD and LOAD share the same pathophysiology and how they res

0 views • 16 slides

The ADNI Private Partner Scientific Board (PPSB) Update for 2015 highlights key leadership, partner organizations, deliverables, and accomplishments in advancing drug development. Susan De Santi as Chairperson, along with industry leaders, plays a crucial role in advising and collaborating with ADNI

0 views • 23 slides

Cutting-edge MRI protocols, ADNI 3, aim to enhance brain imaging techniques for clinical trials, focusing on precise measurements, disease detection, and potential treatment evaluation by leveraging advanced imaging methods like ASL, dMRI, and TF-fMRI.

0 views • 20 slides

The Argentina Alzheimer's Disease Neuroimaging Initiative (arg-ADNI) is a comprehensive program focusing on the early detection and characterization of Alzheimer's disease (AD) and related conditions. The initiative involves inviting and following patients through various stages, including baseline

0 views • 5 slides

Veronika Logovinsky, MD, PhD, chaired the ADNI Private Partner Scientific Board (PPSB) meeting on July 14, 2017. The PPSB, comprising leadership and working groups, focuses on providing advice for ADNI 3 implementation and accelerating drug development. The Clinical Endpoints Working Group, led by V

0 views • 21 slides